Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2007-05-29
2007-05-29
Swope, Sheridan (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S070100, C435S071100, C424S094640
Reexamination Certificate
active
10699393
ABSTRACT:
The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptides that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.
REFERENCES:
patent: 6110721 (2000-08-01), Gibbs et al.
Galye et al, Identification of regions in interleukin-1 alpha important for activity. J. Biol. Chem. Oct. 15, 1993;268(29):22105-11.
Whisstock et al, Prediction of protein function from protein sequence and structure. Q Rev Biophys. Aug. 2003;36(3):307-40. Review.
Cameron, ER., Recent advances in transgenic technology. Mol Biotechnol. Jun. 1997;7(3):253-65. Review.
Ayala et al., Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR1 or protein C. Ann N Y Acad Sci. 2001;936:456-8 (meeting date Aug. 23-26, 2000).
Guo et al, Protein to random amino acid change. Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-9210. Epub Jun. 14, 2004.
Metzler et al, “Cooperative changes in conformation” and “Noncompetitive inhibition and activation; allosteric sites” In:Biochemistry, vol. 1, 2001 pp. 349-350 and 473-477.
Nikoshkov et al, Synergistic effect of partially inactivating mutations in steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. Jan. 1997;82(1):194-9.
Dang et al, An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci U S A. Jun. 20, 1995;92(13):5977-81.
Richardson et al, Crystal structure of the human alpha -thrombin-haemadin complex: an exosite II-binding inhibitor. EMBO J. Nov. 1, 2000;19(21):5650-60.
Tsiang et al, Functional mapping of the surface residues of human thrombin. J. Biol Chem. Jul. 14, 1995;270(28):16854-63.
Arosio, et al. —Mutation of W215 Compromises Thrombin Cleavage of Fibrinogen, but Not of PAR-1 or ProteinC—Biochemistry 39, 8095-8108 (2000).
Bernard, et al.—Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis—N. Engl. J. Med. 344, 699-709 (2001).
Bonniec, et al. —Glu-192 → Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin—Proc. Natl. Acad. Sci. 88, 7371-7375 (1991).
Bouton, et al.—Role of the thrombin insertion loop 144-155, Study of thrombin mutations W148G, K154E and a thrombin-based synthetic peptide—Eur. J. Biochem. 229, 526-532 (1995).
Cantwell & Di Cera—Rational Design of a Potent Anticoagulant Thrombin—Journal of Biological Chemistry 275, 39827-39839 (2000).
Di Cera—Anticoagulant Thrombins—Trends in Cardiovascular Medicine 8, 340-350 (1998).
Gibbs, et al.—Conversion of thrombin into an anticoagulant by protein engineering— Nature 378, 413-416 (1995).
Gresele, et al.—Activated Human Protein C Prevents Thrombin-induced Thromboembolism in Mice—Journal for Clinical Investigation 101, 667-676 (1998).
Gruber, et al.—The Thrombin Mutant W215A/E217A Shows Safe and Potent Antigcoagulant and Antihrombotic Effectsin Vivo—Journal of Biological Chemistry 277, 27581-27584 (2002).
Gruber, et al.—Direct Detection of Activated Protein C in Blood from Human Subjects—Blood 79, 2340-2348 (1992).
Gruber, et al.—Inhibition of Platelet-Dependent Thrombus Formation by Human Activated Protein C in a Primate Model—Blood 73, 639-642 (1989).
Guinto, et al.—Unexpected crucial role of residue 225 in serine proteases—Proc. Natl. Acad. Sci. USA 96, 1852-1857 (1999).
Hanson, et al. —Antithrombotic Effects of Thrombin-induced Activation of Endogenous Protein C in Primates—Journal for Clinical Investigation 92, 2003-2012 (1993).
Harker, et al.—Experimental Arterial Thrombosis in Nonhuman Primates—Circulation 83, IV-41-IV-55 (1991).
Ishii, et al. —Thrombomodulin is Present in Human Plasma and Urine—Journal for Clinical Investigation 76, 2178-2181 (1985).
Kogan, et al.—Protein C Activator from the Venom of Aagkistrodon blomhoffi ussuriensis Retards Thrombus Formation in the Arterio-Venous Shunt in Rats—Thrombosis Research 70, 385-393 (1993).
Leung, et al.—Dissociation of Thrombin's Substrate Interactions Using Site-Directed Mutagenesis—Trends in Cardiovascular Medicine 10, 89-92 (2000).
Marder, et al.—Plasmin Induces Local Thrombolysis without Causing Hermorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit—Thrombosis Haemostasis 86, 739-745 (2001).
Martinoli, et al.—Fast Functional Protein C Assay Using Protac, A Novel Protein C Activator—Thrombosis Research 43, 253-264 (1986).
McBane, et al. —Antithrombotic Action of Endogenous Porcine Protein C Activated with a Latent Porcine Thrombin Preparation—Thrombosis Haemostasis 74, 879-885 (1995).
Richardson, et al.-Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant—Nature 360, 261-264 (1992).
Sheehan, et al. —Mutagenesis of Thrombin Selectivity Modulates Inhibition by Serpins Heparin Cofactor II and Antithrombin III—The Journal of Biological Chemistry 268, 3639-3645 (1993.
Takahashi, et al.—Soluble Thrombomodulin Purified from Human Urine Exhibits a Potent Anticoagulant EffectsIn VitroandIn Vivo—Thrombosis Haeostasis 73, 805-811 (1995).
Taylor, et al. —Protein C Prevents the Coagulopathic and Lethal Effects of Escherichia coli Infusion in the Baboon—Journal for Clinical Investigation 79, 918-925 (1987).
Tsiang, et al. —Protein Engineering Thrombin for Optimal Specificity and Potency of Anticoagulant Activityin Vivo—Biochemistry 35, 16449-16457 (1996).
Vindigni, et al.—Release of Fibrinopeptides by the Slow and Fast Forms of Thrombin—Biochemistry 35, 4417-4426 (1996).
Wu, et al. —Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin—Prco. Natl. Acad. Sci. 88, 6775-6779 (1991).
De Cera Enrico
Gruber Andras
Hanson Stephen R.
Emory University
Morris Manning & Martin
Swope Sheridan
Tingkang Xia Tim
LandOfFree
Antithrombotic thrombin variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antithrombotic thrombin variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antithrombotic thrombin variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782277